International Stem Cell Corporation (OTCBB:ISCO) announced today that
Kenneth Aldrich, Chairman of the Board, and Dr. Ruslan Semechkin,
President and CEO of Lifeline Skin Care® (www.lifelineskincare.com),
a subsidiary of ISCO, which develops and markets stem cell based
anti-aging skincare products, will be addressing recent advances in stem
cell technology at the HBA Global Expo being held June 28 – 30 at the
Jacob K. Javits Convention Center in New York City. This annual
conference attracts more than 15,000 beauty industry professionals and
is one of the largest events in the cosmetics and personal care
industry. Product development and marketing executives attend the annual
HBA conference for education and information on the latest trends in
ingredients and raw materials.
Mr. Aldrich is participating in the "Executive Leadership Panel:
Generating the Future in the Skin Anti-Aging Category," on Tuesday, June
28, at 1:30 p.m. Dr. Semechkin is presenting at the Expo's Anti-Aging
Symposium as an expert on emerging technologies in skincare. Dr.
Semechkin's presentation, titled "Stem Cell Derived Growth Factors - the
Next Breakthrough in Anti-Aging," is scheduled for Wednesday, June 29,
at 1:30 p.m.
International Stem Cell is a world leader in the research and
development of parthenogenetic stem cells for therapeutic applications
and is developing and commercializing stem cell-based research and
cosmetic products through Lifeline Skin Care®. The first
cosmetic products, a defensive day moisture serum and a recovery night
moisture serum containing extracts from human parthenogenetic stem
cells, were launched in November 2010 and are available for purchase
through www.lifelineskincare.com
and selected luxury spas across the United States.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells and the development and
commercialization of cell-based research and cosmetic products. ISCO's
core technology, parthenogenesis, results in the creation of pluripotent
human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical
issues associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenic, homozygous stem
cell line that can be a source of therapeutic cells with minimal immune
rejection after transplantation into hundreds of millions of individuals
of differing genders, ages and racial background. This offers the
potential to create the first true stem cell bank, UniStemCell™. ISCO
also produces and markets specialized cells and growth media for
therapeutic research worldwide through its subsidiary Lifeline Cell
Technology, and cell-based skin care products through its subsidiary
Lifeline Skin Care. More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, product development
and marketing plans, and other opportunities for the company and its
subsidiaries, along with other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
"will," "believes," "plans," "anticipates," "expects," "estimates,")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, competition, regulatory
approvals, need and ability to obtain future capital, application of
capital resources among competing uses, and maintenance of intellectual
property rights. Actual results may differ materially from the results
anticipated in these forward-looking statements and as such should be
evaluated together with the many uncertainties that affect the company's
business, particularly those mentioned in the cautionary statements
found in the company's Securities and Exchange Commission filings. The
company disclaims any intent or obligation to update forward-looking
statements.
International Stem Cell Corporation 760-940-6383 Kenneth C.
Aldrich, Chairman kaldrich@intlstemcell.com Ruslan
Semechkin, PhD Vice President, ISCO President and CEO,
Lifeline Skin Care ras@intlstemcell.com or: Lippert/Heilshorn
& Associates Don Markley, 310-691-7100 dmarkley@lhai.com |